The operating environment for medical technology companies becomes more complex, competitive and costly every year. There is no expectation that 2022 will buck that trend, even as the medtech sector prepares for a third year of working under conditions shaped by the COVID-19 pandemic.

Baxter’s management justified the deal by emphasizing the potential cost synergies and shared commitment to digital health innovation.

Predictions made by Kim Trautman, lead author of the US FDA’s Quality System Regulation, and four other top medtech experts regarding the agency’s upcoming harmonized QSR topped our list of most-read Medtech Insight articles in August.

Media reports indicate Baxter is negotiating to acquire Hillrom for about $10bn, but the companies are not commenting on the reports.